---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-23-000135"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T05:40:40.117441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M

## Summary
- Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).
- Consumables revenue $16.9M (record; +5% YoY) with Revio consumables surpassing Sequel II/IIe.
- GAAP net loss $66.9M ($0.26/shr) vs $77.0M ($0.34/shr) prior year; Non-GAAP net loss $67.9M ($0.27).
- Gross margin 32% vs 42% prior year; non-GAAP gross margin also 32%.
- Cash and investments $767.8M; launched leasing program, first Onso shipments, and new WGS variant pipeline.

## SEC filing metadata
- accession: 0001299130-23-000135
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/0001299130-23-000135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/pacb-20231030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-23-000135
- JSON: https://secwatch.observer/filing/0001299130-23-000135.json
- Plain text: https://secwatch.observer/filing/0001299130-23-000135.txt

## Key facts
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended September 30, 2023 results: revenue $55.7 million, net income Net loss for the third quarter of 2023 was $66.9 million, EPS $0.26.
  - Period: the quarter ended September 30, 2023
  - Revenue: $55.7 million
  - Net income: Net loss for the third quarter of 2023 was $66.9 million
  - EPS: $0.26
  - Result: reported results
  source text: PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results • Revenue of $55.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/0001299130-23-000135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.